small molecule

SEGLENTIS

CELECOXIB; TRAMADOL HYDROCHLORIDE

Loss of exclusivityJune 2031latest FDA-listed patent expiry

CompanyKOWA PHARMACEUTICALS AMERICA INC

Drug detail

Brand name	SEGLENTIS
Active ingredient	CELECOXIB; TRAMADOL HYDROCHLORIDE
Strength	56MG;44MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	October 2021
Marketing status	DISCN

Listed patents

Patent	Expires	Type
8846744	June 2031	product
10548909	April 2030	use U-3244
11478488	April 2030	use U-3244
10238668	April 2030	substance, product
9012440	April 2030	substance, product
10245276	April 2030	substance, product
8598152	April 2030	substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.